Martin Shkreli (Photo by Drew Angerer/Getty Images)
January 18, 2022 07:05 AM ESTUpdated 09:30 AM
People
Pharma

Mar­tin Shkre­li re­ceives life­time in­dus­try ban, forced to re­turn al­most $65M in prof­its af­ter an­ti­com­pet­i­tive scheme

Max Gelman

Senior Editor

Mar­tin Shkre­li will have to find a new nick­name.

A fed­er­al judge banned the for­mer biotech CEO and “Phar­ma Bro” from the drug in­dus­try on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times